The Biotechnology in Germany is a growth engine. According to a new report, all key figures such as employees, turnover and R&D expenditure were at an all-time high in 2016.
The french biotechnology company Vivet Therapeutics has raised €37.5 million in a Series A financing round. Amongst others, Novartis Venture Fund and Roche Venture Fund were involved.
The Boehringer Ingelheim Venture Fund leads a financing consortium that collected €20m for French cancer therapy developer Imcheck. The Marseille-based company also presented its new CEO.
The French biotech said that its lead therapeutic candidate demonstrated the first reduction in HIV reservoirs ever observed in chronically infected HIV patients. Following the news, the company’s share price more than doubled.
British respiratory disease specialist Verona Pharma plc (VRNA) has raised US-$77.8m (€73,96m) at NASDAQ through the issuance of 5,768,000 American Depositary Shares (ADS) – each ADS representing eight ordinary shares – at a price of US-$13.50 per ADS.
Epigenomics and minority shareholder Cathay Fortune International Company have agreed for Cathay to take over the Berlin-based diagnostics company for €7.52 per share – a premium of almost 50%.
Belgian-Dutch antibody developer Argenx N.V. seeks to raise US$74.7m in a US IPO. The company, which is already listed on Euronext wants to use the proceeds to push development of its autoimmune and cancer drugs.
Four orphan drugs, three biosimilars, and one monoclonal antibody therapy have been recommended for EU market approval by the European Medicines Agency’s CHMP this month.
With treatment cost of €1m+ per patient, Glybera was the most expensive therapy ever approved in Europe. Now, Uniqure has decided to terminate post-marketing studies required for prolongation of its existing EU conditional market approval.
Synthetic promoter and gene expression specialist Synpromics has completed a £5.2m (€6.2m) financing round with existing investors.